These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 32382949)
21. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648 [TBL] [Abstract][Full Text] [Related]
22. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711 [TBL] [Abstract][Full Text] [Related]
23. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis. Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831 [TBL] [Abstract][Full Text] [Related]
24. The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia. Sekiguchi N Intern Med; 2022 Dec; 61(23):3473-3474. PubMed ID: 35569973 [No Abstract] [Full Text] [Related]
25. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. Liu J; Chen C; Wang D; Zhang J; Zhang T Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548 [TBL] [Abstract][Full Text] [Related]
26. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626 [TBL] [Abstract][Full Text] [Related]
27. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794 [TBL] [Abstract][Full Text] [Related]
28. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia. Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091 [TBL] [Abstract][Full Text] [Related]
29. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
30. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. Kozaki R; Yasuhiro T; Kato H; Murai J; Hotta S; Ariza Y; Sakai S; Fujikawa R; Yoshida T PLoS One; 2023; 18(3):e0282166. PubMed ID: 36897912 [TBL] [Abstract][Full Text] [Related]
31. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase. Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443 [TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504 [TBL] [Abstract][Full Text] [Related]
33. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
34. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612 [TBL] [Abstract][Full Text] [Related]
35. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment. Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257 [TBL] [Abstract][Full Text] [Related]
37. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
38. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871 [TBL] [Abstract][Full Text] [Related]